Compare ASG & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASG | PLYX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 328.8M | 271.8M |
| IPO Year | 1995 | N/A |
| Metric | ASG | PLYX |
|---|---|---|
| Price | $5.34 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 287.9K | ★ 324.6K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.55 | $2.07 |
| 52 Week High | $5.69 | $9.18 |
| Indicator | ASG | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 38.28 |
| Support Level | $5.23 | $2.32 |
| Resistance Level | $5.40 | $3.41 |
| Average True Range (ATR) | 0.07 | 0.62 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 84.37 | 22.95 |
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.